Effects of surotomycin on Clostridium difficile viability and toxin production in vitro

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4199-4205

  Bouillaut, Laurent ^a   McBride, Shonna ^b   Sorg, Joseph A ^c   Schmidt, Diane J ^d   Suarez, José M ^b,f   Tzipori, Saul ^d   Mascio, Carmela ^e   Chesnel, Laurent ^e   Sonenshein, A L ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

^d TUFTS UNIVERSITY   (United States)

^e CUBIST PHARMACEUTICALS INC   (United States)

^f EY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; LANTIBIOTIC; METRONIDAZOLE; NISIN; POLYMYXIN B; SUROTOMYCIN; VANCOMYCIN; VIRULENCE FACTOR; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; CB-183,315; CYCLOPEPTIDE; ENTEROTOXIN; LIPOPEPTIDE; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE;

ARTICLE; BACTERIAL CELL; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG EFFECT; EXPOSURE; GENE EXPRESSION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; SPORE GERMINATION; BACTERIAL SPORE; BIOSYNTHESIS; CELL WALL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION;

ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CELL WALL; CLOSTRIDIUM DIFFICILE; ENTEROTOXINS; GENE EXPRESSION REGULATION, BACTERIAL; LIPOPEPTIDES; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MUTATION; PEPTIDES, CYCLIC; SPORES, BACTERIAL; VANCOMYCIN; VIRULENCE FACTORS;

EID: 84935923575     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00275-15     Document Type: Article

References (30)

1. Bartlett JG. 2010. Clostridium difficile: progress and challenges. Ann N Y Acad Sci 1213:62-69. http://dx.doi.org/10.1111/j.1749-6632.2010.05863.x.
2. Miller BA, Chen LF, Sexton DJ, Anderson DJ. 2011. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 32:387-390. http://dx.doi.org/10.1086/659156.
3. Kelly CP, LaMont JT. 2008. Clostridium difficile - more difficult than ever. N Engl J Med 359:1932-1940. http://dx.doi.org/10.1056/NEJMra0707500.
4. Jarvis WR, Schlosser J, Jarvis AA, Chinn RY. 2009. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 37:263-270. http://dx.doi.org/10.1016/j.ajic.2009.01.001.
5. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422-431. http://dx.doi.org/10.1056/NEJMoa0910812.
6. Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. 2007. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 102:2781-2788. http://dx.doi.org/10.1111/j.1572-0241.2007.01539.x.
7. Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. 2012. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 40:1-8. http://dx.doi.org/10.1016/j.ijantimicag.2012.01.004.
8. Rupnik M, Wilcox MH, Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7:526-536. http://dx.doi.org/10.1038/nrmicro2164.
9. Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN. 2012. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 55:351-357. http://dx.doi.org/10.1093/cid/cis430.
10. Sorg JA, Sonenshein AL. 2008. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 190:2505-2512. http://dx.doi.org/10.1128/JB.01765-07.
11. Setlow P. 2003. Spore germination. Curr Opin Microbiol 6:550-556. http://dx.doi.org/10.1016/j.mib.2003.10.001.
12. Paredes-Sabja D, Shen A, Sorg JA. 2014. Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol http://dx.doi.org/10.1016/j.tim.2014.04.003.
13. Setlow P. 2014. Germination of spores of Bacillus species: what we know and do not know. J Bacteriol 196:1297-1305. http://dx.doi.org/10.1128/JB.01455-13.
14. Allen CA, Babakhani F, Sears P, Nguyen L, Sorg JA. 2013. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrob Agents Chemother 57:664-667. http://dx.doi.org/10.1128/AAC.01611-12.
15. McBride SM, Sonenshein AL. 2011. The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile. Microbiology 157: 1457-1465. http://dx.doi.org/10.1099/mic.0.045997-0.
16. McBride SM, Sonenshein AL. 2011. Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile. Infect Immun 79:167-176. http://dx.doi.org/10.1128/IAI.00731-10.
17. Suárez JM, Edwards AN, McBride SM. 2013. The Clostridium difficile cpr locus is regulated by a noncontiguous two-component system in response to type A and B lantibiotics. J Bacteriol 195:2621-2631. http://dx.doi.org/10.1128/JB.00166-13.
18. Mascio CT, Chesnel L, Thorne G, Silverman JA. 2014. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 58:3976-3982. http://dx.doi.org/10.1128/AAC.00124-14.
19. Mascio CT, Mortin LI, Howland KT, Van Praagh AD, Zhang S, Arya A, Chuong CL, Kang C, Li T, Silverman JA. 2012. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother 56:5023-5030. http://dx.doi.org/10.1128/AAC.00057-12.
20. Killgore GTA, Johnson S, Brazier J, Kuijper E, Pepin J, Frost EH, Savelkoul P, Nicholson B, van den Berg RJ, Kato H, Sambol SP, Zukowski W, Woods C, Limbago B, Gerding DN, McDonald LC. 2008. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J Clin Microbiol 46:431-437. http://dx.doi.org/10.1128/JCM.01484-07.
21. Sorg JA, Dineen SS. 2009. Laboratory maintenance of Clostridium difficile. Curr Protoc Microbiol Chapter 9:Unit9A.1. http://dx.doi.org/10.1002/9780471729259.mc09a01s12.
22. Edwards AN, Suarez JM, McBride SM. 2013. Culturing and maintaining Clostridium difficile in an anaerobic environment. J Vis Exp 2013:e50787. http://dx.doi.org/10.3791/50787.
23. CLSI. 2015. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI, Wayne, PA.
24. Sorg JA, Sonenshein AL. 2010. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol 192:4983-4990. http://dx.doi.org/10.1128/JB.00610-10.
25. Francis MB, Allen CA, Shrestha R, Sorg JA. 2013. Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog 9:e1003356. http://dx.doi.org/10.1371/journal.ppat.1003356.
26. Bouillaut L, McBride SM, Sorg JA. 2011. Genetic manipulation of Clostridium difficile. Curr Protoc Microbiol Chapter 9:Unit 9A.2. http://dx.doi.org/10.1002/9780471729259.mc09a02s20.
27. Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108. http://dx.doi.org/10.1038/nprot.2008.73.
28. Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, Bedenice D, Webb RP, Wright PM, Smith LA, Tzipori S, Shoemaker CB. 2012. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One 7:e29941. http://dx.doi.org/10.1371/journal.pone.0029941.
29. Yang G, Zhou B, Wang J, He X, Sun X, Nie W, Tzipori S, Feng H. 2008. Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol 8:192. http://dx.doi.org/10.1186/1471-2180-8-192.
30. Löfmark S, Edlund C, Nord CE. 2010. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 50(Suppl 1):S16-S23. http://dx.doi.org/10.1086/647939.